37 unchanged sentences
(c) Issuer Purchases of Equity Securities
−Removed: Selected Financial Data
−Removed: The following tables set forth our selected consolidated financial data for the periods and as of the dates indicated.
−Removed: You should read the following selected consolidated financial data in conjunction with our audited consolidated financial statements and the related notes thereto included elsewhere in this Annual Report and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of this Annual Report.
−Removed: The selected consolidated financial data set forth below as of December 31, 2020 and 2019, and for the years ended December 31, 2020, 2019 and 2018, are derived from our audited consolidated financial statements included elsewhere in this Annual Report.
−Removed: The selected consolidated financial data set forth below as of December 31, 2018, 2017, and 2016, and for the years ended December 31, 2017 and 2016, are derived from our audited consolidated financial statements contained in reports previously filed with the SEC, not included herein.
−Removed: Our audited consolidated financial statements have been prepared in United States dollars in accordance with U.S.
−Removed: The selected consolidated financial data in the below tables have been adjusted to reflect the effects of discontinued operations.
−Removed: See "Notes to the Consolidated Financial Statements - Note 3" appearing elsewhere in this Annual Report.
−Removed: Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.
−Removed: Year Ended December 31,
−Removed: 2020 2019 2018 2017 2016
−Removed: (In thousands, except share and per share amounts)
−Removed: Statements of Operations Data:
−Removed: Collaboration and licensing revenues $ 21,208 $ 14,059 $ 69,540 $ 134,624 $ 97,160
−Removed: Product revenues 24,349 23,780 28,486 33,585 36,958
−Removed: Service revenues 56,899 51,803 52,419 50,611 43,049
−Removed: Total revenues (1) 103,178 90,722 151,178 219,463 177,607
−Removed: Total operating expenses 189,781 257,511 520,845 285,354 252,424
−Removed: Operating loss (86,603) (166,789) (369,667) (65,891) (74,817)
−Removed: Loss from continuing operations (103,773) (170,334) (380,487) (50,420) (131,838)
−Removed: Net loss attributable to noncontrolling interests — 1,592 5,370 9,802 3,662
−Removed: Net loss from continuing operations attributable to Precigen (103,773) (168,742) (375,117) (40,618) (128,176)
−Removed: Net loss from continuing operations attributable to Precigen per share, basic and diluted $ (0.62) $ (1.09) $ (2.90) $ (0.34) $ (1.09)
−Removed: Weighted average shares outstanding, basic and diluted 167,065,539 154,138,774 129,521,731 119,998,826 117,983,836
−Removed: 2020 2019 2018 2017 2016
−Removed: (In thousands)
−Removed: Balance Sheet Data:
−Removed: Cash and cash equivalents $ 51,792 $ 65,793 $ 96,876 $ 59,251 $ 60,217
−Removed: Short-term and long-term investments 48,325 9,260 119,614 6,273 180,595
−Removed: Total assets (2) 314,587 455,763 716,177 846,851 949,068
−Removed: Deferred revenue, current and non-current (1) 25,823 53,833 57,816 226,343 298,842
−Removed: Long-term debt (3) 171,882 217,991 211,695 8,037 7,948
−Removed: Other liabilities (4) 49,708 112,228 67,944 65,926 73,030
−Removed: Total Precigen shareholders' equity 67,174 71,711 362,855 533,631 560,237
−Removed: Noncontrolling interests — — 15,867 12,914 9,011
−Removed: Total equity 67,174 71,711 378,722 546,545 569,248
−Removed: (1) Revenues and deferred revenue in 2020, 2019, and 2018 are accounted for under ASC Topic 606, Revenue from Contracts with Customers , or ASC 606, and revenues and deferred revenue prior to 2018 are accounted for under ASC 605, Revenue Recognition , or ASC 605.
−Removed: We adopted ASC 606 on January 1, 2018 using the modified retrospective method, which applies the changes in accounting prospectively and does not restate prior periods.
−Removed: See "Notes to the Consolidated Financial Statements - Notes 4, 6, and 18" for discussions of transactions in 2018 resulting in a decrease in the balances of deferred revenue.
−Removed: (2) Total assets include $191, $161,225, and $129,545 of investments in preferred stock as of December 31, 2018, 2017, and 2016, respectively.
−Removed: In conjunction with the ZIOPHARM License Agreement in 2018, all of our ZIOPHARM preferred shares were returned to ZIOPHARM.
−Removed: See "Notes to the Consolidated Financial Statements - Notes 10 and 11" for discussions of impairment losses on goodwill and other noncurrent assets recognized in 2020 and 2019.
−Removed: (3) In 2018, we completed a registered underwritten public offering of $200,000 aggregate principal amount of Convertible Notes.
−Removed: (4) Other liabilities include $8,801 of deferred consideration as of December 31, 2016.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.